The estimated Net Worth of Frederique Ph.D. Menzaghi is at least $7.6 Million dollars as of 23 June 2023. Frederique Menzaghi owns over 2,993 units of Cara Therapeutics Inc stock worth over $44,587 and over the last 11 years he sold CARA stock worth over $5,328,941. In addition, he makes $2,226,630 as Senior Vice President, Research and Development, and Chief Scientific Officer at Cara Therapeutics Inc.
Frederique has made over 51 trades of the Cara Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 2,993 units of CARA stock worth $10,505 on 23 June 2023.
The largest trade he's ever made was exercising 40,000 units of Cara Therapeutics Inc stock on 1 November 2018 worth over $82,000. On average, Frederique trades about 5,928 units every 46 days since 2014. As of 23 June 2023 he still owns at least 153,747 units of Cara Therapeutics Inc stock.
You can see the complete history of Frederique Menzaghi stock trades at the bottom of the page.
Dr. Frederique Menzaghi Ph.D. serves as Senior Vice President, Research and Development, Chief Scientific Officer of the Company. She has served as our Senior Vice President, Research and Development since 2017 and our Chief Scientific Officer since March 2019. Dr. Menzaghi has over 25 years of drug development and management experience in biotechnology in the field of ion channels and G protein-coupled receptors. Her expertise ranges from exploratory non-clinical research through clinical development. From 2003 to 2004, she served as Vice President, Pharmacology and Business Development at Psychogenics Inc., a preclinical contract research organization. From 1999 to 2003, she was the Research Director of In Vivo Pharmacology at Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), leading a multidisciplinary research team. Prior to that, Dr. Menzaghi established and directed a preclinical research laboratory at SIBIA Neurosciences (acquired by Merck). Her research expertise ranged from the development of small molecules to small peptides. She has extensive experience with corporate partnering with large U.S. and Asian pharmaceutical companies including Eli Lilly, Merck and J&J. Dr. Menzaghi received her Ph.D. in Neurosciences from the University of Louis Pasteur, Strasbourg, France and her M.Sc. in clinical psychology from the University of Nancy, France, after which she conducted her post-doctoral research at the Scripps Research Institute, San Diego, California. She has over 55 peer-reviewed publications and book chapters, 100 international meeting presentations and is listed as an inventor on numerous patents.
As the Senior Vice President, Research and Development, and Chief Scientific Officer of Cara Therapeutics Inc, the total compensation of Frederique Menzaghi at Cara Therapeutics Inc is $2,226,630. There are 2 executives at Cara Therapeutics Inc getting paid more, with Joana Goncalves having the highest compensation of $3,736,190.
Frederique Menzaghi is 53, he's been the Senior Vice President, Research and Development, and Chief Scientific Officer of Cara Therapeutics Inc since 2019. There are 10 older and 8 younger executives at Cara Therapeutics Inc. The oldest executive at Cara Therapeutics Inc is Harrison Bains, 76, who is the Independent Director.
Frederique's mailing address filed with the SEC is 9th, 107 Elm St, Stamford, CT 06902, USA.
Over the last 11 years, insiders at Cara Therapeutics Inc have traded over $25,200,591 worth of Cara Therapeutics Inc stock and bought 1,874,453 units worth $19,406,983 . The most active insiders traders include Edward Hurwitz, Martin Vogelbaum, and Ventures Vi Lprmv Vi, L.L.C.... On average, Cara Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $5,343. The most recent stock trade was executed by Christopher Posner on 1 August 2024, trading 4,149 units of CARA stock currently worth $1,452.
cara therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. cara's most advanced patented compound, cr845, is currently undergoing clinical testing for acute pain and uremic pruritus. this compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. in addition, cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.
Cara Therapeutics Inc executives and other stock owners filed with the SEC include: